ClinicalTrials.gg
Status unknownNCT03762967Updated Oct 22, 2020

Autologous Adipose-Derived Adult Stromal Vascular Cell Administration for Male Patients With Infertility

A Phase 2 interventional study of Lipoaspiration and SVF introduction. and Standard therapy. in Azoospermia and Oligozoospermia, sponsored by State-Financed Health Facility "Samara Regional Medical Center Dinasty". Status unknown at 1 site in Russian Federation. Open to male participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-10-22.

Sponsored by State-Financed Health Facility "Samara Regional Medical Center Dinasty" · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2020), so the status shown — last known as Enrolling by invitation — may be out of date.

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Mar 2018, registered Nov 2018).
Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

Severe Oligospermia (oligozoospermia) refer to semen with a low concentration of sperm and is a common finding in male infertility. Often semen with a decreased sperm concentration may also show significant abnormalities in sperm morphology and motility that affect Male fertility. The purpose of this study is to assess the ability of Autologous Adipose-Derived Adult Stromal Vascular Fraction (SVF) cells to stimulate Sertoli and spermatogonia cells and affect male fertility.

Read the detailed description

This is an open-label study to evaluate efficiency of administration of Autologous Adipose-Derived Adult Stromal Vascular Fraction (SVF) in the testis in patients with oligospermia and azoospermia.

Forty men with several form oligozoospermia and azoospermia will be recruited for the study. 20 patients with same diagnosis served as a control with standard medications.Other patients -10 with oligospermia and 10 with azoospermia will receive standard medication and SVF injections.

The diagnosis of Azoospermia (Oligospermia) will be established on the basis of two and more semen analysis evaluations done at separate occasions and detailed history taking, physical examination and investigations (blood tests include hormon levels as testosteron. follicle stimulating hormone (FSH), luteinizing hormone (LH). karyotyping and testosterone levels, and may include testicular biopsy or transrectal ultrasound if indicated.

This study affect only Pretesticular and Testicular forms, without chromosomal aberration. SVF can produce a lot of cytokines ( as EGF, FGF, NGF, PDGF, VEGF, IGF, GMCSF, GCSF, TGF, Erythropoetin, TPO, BMP, HGF, GDF, Neurotrophins, MSF, SGF, GDF and growth factors) moreover the microvesicles and exosomes released by this cells can prevent cells from apoptosis and stimulate regenerative process of surrounding tissues and cells.

SVF will be transplanted by an andrological surgeon through a standard surgical approach. Subjects will be monitored frequently for a total of one year after cell injection.

02

Conditions studied

  • Azoospermia
  • Oligozoospermia

Keywords

  • Autologous Stem Cell
  • Male infertility
  • Adipose-Derived stem cell
  • Azoospermia
  • Oligospermia
03

In context

Azoospermia

59 studies on the registry are indexed under Azoospermia; 17 are open to participants now.

This study's planned enrollment of 40 is below the median of 57 across 32 interventional studies indexed under Azoospermia.

Browse Azoospermia studies →

Lead sponsor

State-Financed Health Facility "Samara Regional Medical Center Dinasty" is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • idiopathic oligozoospermia (spermatozoid number \<2x10\^6/mL) - 10 patients
  • cryptozoospermia/azoospermia - 10 patients

Exclusion criteria

Exclusion Criteria:

  • age before 18 or after 60 years old
  • heart insufficiency. stroke (during 1 year)
  • anemia
  • blood disease
  • pelvis bone trauma
  • chronic diseases in decompensation stage
  • skin diseases
  • tuberculosis
  • hyperprolactinaemia
  • hyper or hypothyreosis
  • obstructive zoospermia
  • sperm stimulating hormone therapy
  • Men with previous surgery in testis
  • Men with infectious genital diseases and anatomical abnormalities of the genital tract
  • Those with major medical problems such as , . C, etc.
  • Chromosomal aberration (e.g. Y microdeletion, trisomy....)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Lipoaspiration and SVF introduction I.

    Patients with azoospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.

    Biological: Lipoaspiration and SVF introduction. · Drug: Standard therapy.

  • Active comparator
    Standard therapy I.

    Patients with azoospermia that introduce with Standard therapy only.

    Drug: Standard therapy.

  • Experimental
    Lipoaspiration and SVF introduction II

    Patients with oligospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.

    Biological: Lipoaspiration and SVF introduction. · Drug: Standard therapy.

  • Active comparator
    Standard therapy II.

    Patients with oligospermia that introduce with Standard therapy only.

    Drug: Standard therapy.

Interventions

  • BiologicalLipoaspiration and SVF introduction.

    Lipoaspiration, isolation of SVF and introduction into testis Interstitium.

  • DrugStandard therapy.

    Standard therapy include to give up bad habits, to establish a healthy diet, to eliminate excessive physical exertion. eliminate. In the case of endocrine disorders, hormone therapy is prescribed.

    Also known as: healthy diet, physical exertion eliminate. hormone therapy.

06

What researchers measure

Primary outcomes

  1. sperm concentration in ejaculate

    Sperm quantity and quality will be evaluated with automatic sperm cout analyzer a month, two and three after injection of SVF. Total measures - 3.

    Time frame: 1, 2, 3 month

  2. Spermatozoa in testicular biopsy

    Testicular sperm aspiration (TESA) will be performed after 3 month after SVF injection.

    Time frame: 3 month

Secondary outcomes

  1. Testosterone

    Testosterone will be measured a three month after injection of SVF.

    Time frame: 3 month

  2. Inhibin-B

    Inhibin-B will be measured a three month after injection of SVF.

    Time frame: 3 month

  3. Follicle stimulating hormone (FSH)

    Follicle stimulating hormone will be measured a three month after injection of SVF.

    Time frame: 3 month

07

Study locations

1 site
  • Medical Centre Dinasty
    Samara, 443095, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2018 (actual). Primary completion is estimated for Dec 2020, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2018
First posted
Dec 4, 2018
StartActual
Mar 12, 2018
Primary completionEst.
Dec 30, 2020
CompletionEst.
Dec 30, 2021
Last update
Oct 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03762967
Lead sponsor
State-Financed Health Facility "Samara Regional Medical Center Dinasty"
Responsible party
Volchkov Stanislav (Deputy director, Quality assurance director, State-Financed Health Facility "Samara Regional Medical Center Dinasty") — Principal investigator
First posted
Dec 4, 2018
Start date
Mar 12, 2018
Primary completion
Dec 30, 2020 (estimated)
Completion
Dec 30, 2021 (estimated)
Last update
Oct 22, 2020

Study contacts

Olga Tyumina, M.D. P.h.D.
study chair · Medical Centre Dinasty

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion